Tiverton Asset Management LLC held its position in Celgene Corporation (NASDAQ:CELG) during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 247,766 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Celgene Corporation makes up approximately 1.7% of Tiverton Asset Management LLC’s investment portfolio, making the stock its 11th biggest holding. Tiverton Asset Management LLC’s holdings in Celgene Corporation were worth $32,177,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in the company. Toronto Dominion Bank boosted its position in shares of Celgene Corporation by 22.6% during the 1st quarter. Toronto Dominion Bank now owns 413,342 shares of the biopharmaceutical company’s stock valued at $51,426,000 after acquiring an additional 76,322 shares during the last quarter. Eagle Asset Management Inc. boosted its position in shares of Celgene Corporation by 1.5% during the 1st quarter. Eagle Asset Management Inc. now owns 20,128 shares of the biopharmaceutical company’s stock valued at $2,504,000 after acquiring an additional 295 shares during the last quarter. Warren Averett Asset Management LLC acquired a new position in shares of Celgene Corporation during the 1st quarter valued at about $438,000. Harel Insurance Investments & Financial Services Ltd. acquired a new position in shares of Celgene Corporation during the 1st quarter valued at about $118,000. Finally, Sawtooth Solutions LLC boosted its position in shares of Celgene Corporation by 19.8% during the 1st quarter. Sawtooth Solutions LLC now owns 8,307 shares of the biopharmaceutical company’s stock valued at $1,034,000 after acquiring an additional 1,375 shares during the last quarter. 79.48% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Tiverton Asset Management LLC Has $32,177,000 Position in Celgene Corporation (CELG)” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.thecerbatgem.com/2017/11/20/tiverton-asset-management-llc-has-32177000-position-in-celgene-corporation-celg.html.

Several brokerages have recently weighed in on CELG. BMO Capital Markets boosted their price target on shares of Celgene Corporation from $148.00 to $155.00 and gave the company an “outperform” rating in a research report on Friday. Canaccord Genuity set a $140.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday. Oppenheimer Holdings, Inc. set a $166.00 price target on shares of Celgene Corporation and gave the company a “buy” rating in a research report on Thursday. Mizuho reissued a “buy” rating on shares of Celgene Corporation in a research report on Friday, November 3rd. Finally, Cantor Fitzgerald reissued a “hold” rating and set a $112.00 price target on shares of Celgene Corporation in a research report on Monday, October 30th. One analyst has rated the stock with a sell rating, eleven have issued a hold rating, nineteen have assigned a buy rating and two have given a strong buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $139.87.

Celgene Corporation (NASDAQ:CELG) opened at $104.10 on Monday. The company has a market cap of $81,959.70, a P/E ratio of 16.27, a price-to-earnings-growth ratio of 0.80 and a beta of 1.79. Celgene Corporation has a one year low of $94.55 and a one year high of $147.17. The company has a quick ratio of 3.52, a current ratio of 3.65 and a debt-to-equity ratio of 1.31.

Celgene Corporation (NASDAQ:CELG) last announced its quarterly earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.87 by $0.04. The company had revenue of $3.29 billion for the quarter, compared to analyst estimates of $3.42 billion. Celgene Corporation had a net margin of 27.36% and a return on equity of 63.80%. The firm’s revenue was up 10.2% on a year-over-year basis. During the same period in the prior year, the firm posted $1.58 earnings per share. equities research analysts anticipate that Celgene Corporation will post 6.67 EPS for the current fiscal year.

In other Celgene Corporation news, Director Michael D. Casey sold 9,250 shares of the stock in a transaction that occurred on Tuesday, September 5th. The shares were sold at an average price of $139.03, for a total value of $1,286,027.50. Following the transaction, the director now directly owns 9,250 shares in the company, valued at $1,286,027.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Terrie Curran sold 1,727 shares of the stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $143.89, for a total value of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. Insiders sold 20,227 shares of company stock worth $2,843,956 over the last quarter. 0.95% of the stock is currently owned by insiders.

Celgene Corporation Profile

Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

Institutional Ownership by Quarter for Celgene Corporation (NASDAQ:CELG)

Receive News & Stock Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related stocks with our FREE daily email newsletter.